Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.
The activity of cefpirome against gram-positive isolates from cancer patients was compared to that of currently available extended-spectrum cephalosporins. Cefpirome was active against methicillin-susceptible, coagulase-positive, and coagulase-negative staphylococci. It was the most active agent against streptococci belonging to Lancefield groups A, B and G and Streptococcus pneumoniae. 76% of enterococcal isolates were susceptible to cefpirome - far more than any of the other agents tested.
D002511:Cephalosporins / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*; D000097572:Cefpirome
D002511:Cephalosporins; D000097572:Cefpirome